Amphista Therapeutics

A new approach to protein degradation

Amphista Therapeutics is using a novel mechanism of targeted protein degradation (TPD) to hijack the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression.

Powered by transformational science, they are advancing beyond traditional degrader approaches using their proprietary Eclipsys™ Drug Development Platform. Amphista’s approach to protein degradation differentiates from traditional TPD technologies by expanding the scope for therapeutic applications and reducing the risk of resistance in oncology indications.

CEO  Beverley Carr

Advent Contact  Dominic Schmidt

Advent founded and seeded Amphista in 2018.
Private Companies
24 January 2024 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

Press Release.   Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders   First demonstration of efficacy in disease-relevant in…
Read More
26 September 2023 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Press Release.   PRESS RELEASE   Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb   Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company”…
Read More
4 May 2023 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Press Release.   Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb 4 May 2023 CAMBRIDGE, UK, May 4, 2023 - Amphista Therapeutics, a leader in next…
Read More
12 September 2022 in Amphista Therapeutics, Press Release, Private Companies

Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022

Press Release.   Cambridge, UK – September, 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it…
Read More